Glenmark Pharmaceuticals Launched Latest-in-Class Diabetes Medicine Remogliflozin
News Desk, News Nation 360 : Glenmark Pharmaceuticals Ltd a.k.a Glenmark, a research-led global integrated pharmaceutical company, announced the launch of its novel, patent protected and globally researched sodium glucose co-transporter (SGLT2) inhibitor Remogliflozinetabonate (Remogliflozin) in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors in the proximal convoluted tubule of the kidney, thereby preventing renal re-absorption of glucose and promoting excretion of glucose in the urine. Along with providing
glycemic control, SGLT2 inhibitors help induce weight loss and reduce cardiovascular risks. Glenmark has launched Remogliflozin in India under brand names Remo and Remozen. Glenmark has received regulatory approval for Remogliflozinetabonate 100 mg after successfully completing Phase 3 clinical trials in which Remogliflozin demonstrated good efficiency and safety profile in a head-to-head comparison against Dapagliflozin.
Pic : Krishnendu Kundu
Report : Anustup Kundu